2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-178287
    TNF-α-IN-27 340307-20-2 98%
    TNF-α-IN-27 (Compound 1) is a TNF-α inhibitor with inhibition rate of 64% at 10 μM. TNF-α-IN-27 can be used for the researches of inflammation and immunology, such as asthma.
    TNF-α-IN-27
  • HY-178320
    LAG-3-IN-2 724757-58-8
    LAG-3-IN-2 (Compound LG-17) is a LAG-3 inhibitor. LAG-3-IN-2 can be used for the study of immunology.
    LAG-3-IN-2
  • HY-178327
    DGKα&ζ-IN-2 3039488-61-1
    DGKα/ζ-IN-2 is a potent, orally active and selective dual DGKα/ζ inhibitor with IC50 values of 23 nM (DGKα) and 1.2 nM (DGKζ). DGKα/ζ-IN-2 exhibits selectivity over other DGK isoforms, such as DGKβ and DGKγ. DGKα/ζ-IN-2 shows robust and dose-dependent immune activation in the presence of antigen presentation in an OT-1 murine model. DGKα/ζ-IN-2 can be used for antitumor immunity.
    DGKα&ζ-IN-2
  • HY-178328
    VDR agonist 4
    VDR agonist 4 is an orally active potent VDR agonist. VDR agonist 4 exerts VDR-dependent antifibrotic activity by regulating multiple fibrosis-related genes to suppress α-SMA and collagen I production, thereby inhibiting hepatic stellate cell (HSC) activation. VDR agonist 4 improves CCl4 (HY-RS16594)-induced hepatic fibrosis in mice. VDR agonist 4 can be used for liver fibrosis research.
    VDR agonist 4
  • HY-178332
    sEH/PPARδ modulator 1
    sEH/PPARδ modulator 1 is a sEH/PPARδ dual modulator. sEH/PPARδ modulator 1 can inhibit sEH with an IC50 of 0.46 μM and activate PPARδ with an EC50 of 0.12 μM. sEH/PPARδ modulator 1 can be used for the researches of inflammation, metabolic and cardiovascular disease.
    sEH/PPARδ modulator 1
  • HY-178336
    AC-340 3109965-54-7 98%
    AC-340 is a potent hybrid VDR agonist/HDAC inhibitor. AC-340 superinduces VDR target genes (e.g., CYP24A1) and inhibits HDAC6 (IC50 = 0.37 μM) with ~10-fold selectivity over HDAC2. AC-340 induces VDR hyperagonism by causing widespread protein hyperacetylation (e.g., tubulin and H3K9/K27), which leads to elevated H3K27 acetylation on VDR target genes. AC-340 can be used for melanoma cancer research.
    AC-340
  • HY-178342
    Xanthine oxidase-IN-18 98%
    Xanthine oxidase-IN-18 is a potent orally activeXanthine oxidase (XO) inhibitor (IC50 = 0.263 μM). Xanthine oxidase-IN-18 exerts inhibition by directly and stably binding to the xanthine oxidase Mo-co active site. Xanthine oxidase-IN-18 exhibits reactive oxygen species (ROS) scavenging activity. Xanthine oxidase-IN-18 shows anti-hyperuricemia effects in a Potassium oxonate (HY-17511)-induced hyperuricemic rat model. Xanthine oxidase-IN-18 can be used for hyperuricemia, breast and lung cancer research.
    Xanthine oxidase-IN-18
  • HY-178352
    MAO-B-IN-49 3098883-91-8 98%
    MAO-B-IN-49 is a selective and reversible MAO-B inhibitor (IC50 of 1 nM for human MAO-B). MAO-B-IN-49 shows much higher selectivity for MAO-B than for MAO-A (IC50 = 633.9 μM). MAO-B-IN-49 can reduce ROS production induced by Lipopolysaccharides (HY-D1056) (LPS) in HT22 cells. MAO-B-IN-49 demonstrates substantial neuroprotective properties and significantly improves motor dysfunction in MPTP (HY-W114750)-induced mouse models of Parkinson’s disease (PD). MAO-B-IN-49 can be used for the study of PD.
    MAO-B-IN-49
  • HY-178353
    EGFR/Cytokine-IN-1 98%
    EGFR/Cytokine-IN-1 is an EGFR (IC50 = 0.03 μM) and Cytokine inhibitor (TNF-α, IC50 = 3.1 μM; IL-6, IC50 = 1.6 μM). EGFR/Cytokine-IN-1 shows potent anticancer activity on A549 and MCF7, respectively. EGFR/Cytokine-IN-1 significantly reduces IL-6 and TNF-α levels in A549 cells, and also shows promising ADMET profiles. EGFR/Cytokine-IN-1 can induce apoptosis in a dose-dependent manner. compound 5h can be used for the study of breast cancer and lung cancer.
    EGFR/Cytokine-IN-1
  • HY-178356
    BChE-IN-44
    BChE-IN-44 is a potent, brain-penetrant, highly selective BChE inhibitor [equine BChE IC50 = 18.00 pM, human BChE IC50 = 1.50 nM]. BChE-IN-44 shows neuroprotective effects against the Aβ1-42-induced injury model and inhibitory effects on Aβ1-42 self-aggregation. BChE-IN-44 reduces the levels of inflammatory factors (NO, IL-6, and TNF-α) in Lipopolysaccharides (HY-D1056)-induced BV2 cells. BChE-IN-44 can significantly ameliorate Scopolamine (HY-N0296)-induced cognition impairment. BChE-IN-44 exhibits capacity in the regulation of BChE and acetylcholine levels in the mouse hippocampus. BChE-IN-44 can be used for the study of Alzheimer’s disease (AD).
    BChE-IN-44
  • HY-178360
    NP1192 2966791-41-1
    NP1192 is a potent, selective PROTAC NAT10 degrader that depletes NAT10 protein and inhibits ac4C modification in cancer cells. NP1192 demonstrates dual inhibition of hypoxia-driven glycolysis and immunosuppression via NAT10/HIF-1α/PD-L1 axis disruption, achieving superior antitumor efficacy and synergizing with anti-PD-L1 both in vitro and in vivo. NP1192 can be used for ovarian, cervical, and glioblastoma cancer research. (Blue: CRBN ligand (HY-148834); Black: linker; Pink: NAT10 ligand (HY-16706)).
    NP1192
  • HY-178365
    PAD-IN-4 98%
    PAD-IN-4 is a potent PAD inhibitor (PAD 1/4, IC50 = 0.273/0.24 μM). PAD-IN-4 shows no significant cytotoxicity against A549 or MDA-MB-231 cells. PAD-IN-4 can be used for the study of cancer and autoimmune diseases.
    PAD-IN-4
  • HY-178372
    GSTO1-IN-4 158890-33-6
    GSTO1-IN-4 is a selective, potent GSTO1-1 inhibitor (IC50 = 0.04 μM; KI = 0.16 μM). GSTO1-IN-4 shows low inhibition to GSTO2-2, GSTA1-1 and GSTP1-1. GSTO1-IN-4 shows a capacity to attenuate inflammation in mice and to significantly enhance the cytotoxicity of Cisplatin (HY-17394). GSTO1-IN-4 can be used for the study of inflammation and breast cancer.
    GSTO1-IN-4
  • HY-178380
    HDAC8-IN-14
    HDAC8-IN-14, a curcuminoid derivative, is a selective HDAC8 inhibitor with a Ki of 9 nM. HDAC8-IN-14 induces the production of reactive oxygen species (ROS), disrupts mitochondrial membrane potential, and promotes apoptosis. HDAC8-IN-14 can significantly promote the accumulation of cells in the sub-G0/G1 phase, consistent with apoptotic or necrotic cell death. HDAC8-IN-14 induces upregulation of cytochrome c, cleaved caspase-3, and the pro-apoptotic protein Bak while leaving the anti-apoptotic Bcl-2 levels unaltered. HDAC8-IN-14 can be used for the study of leukemia.
    HDAC8-IN-14
  • HY-178434
    BRP-821
    BRP-821 is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 of 0.4 nM. BRP-821 can be used for the researches of inflammation, cardiovascular, metabolic and neurological disease .
    BRP-821
  • HY-178440
    EGFR/COX-2-IN-2
    EGFR/COX-2-IN-2 (Compound 10a) is a dual inhibitor targeting epidermal growth factor receptor (EGFR) (IC50= 6.0 μM) and cyclooxygenase-2 (COX-2) (IC50=50 μM). EGFR/COX-2-IN-2 induces S-phase cell cycle arrest and apoptosis. EGFR/COX-2-IN-2 is promising for research of cancers and inflammation-related diseases.
    EGFR/COX-2-IN-2
  • HY-178448
    EGFR-IN-178
    EGFR-IN-178 is an orally active EGFR mutant inhibitor, exhibits highly selective inhibitory activity against mutants of the EGFR enzyme, including Del19 (IC50 = 3.4 nM), L858R/T790 M (IC50 = 2.9 nM), and Del19/T790 M (IC50 = 2.5 nM). EGFR-IN-178 has good activity against JAK2 (IC50 = 55.6 nM) and JAK3 (IC50 = 46.1 nM) kinases. EGFR-IN-178 can increase cellular lipid oxide MDA, meanwhile decrease GSH content, causing ferroptosis in cancer cells. EGFR-IN-178 promotes apoptosis by increasing cleaved caspase-3 expression. EGFR-IN-178 can inhibit the phosphorylation of EGFR protein and decrease the active form p-JAK2 for JAK2, induce an increase in intracellular ROS. EGFR-IN-178 can be used for the study of non-small cell lung cancer (NSCLC).
    EGFR-IN-178
  • HY-178464
    RIPK1-IN-34 3065634-19-4 98%
    RIPK1-IN-34 is a selective, brain-penetrant RIPK1 inhibitor (IC50 = 126.70 nM) with almost no inhibitory effect on RIPK3 (IC50 ＞ 10, 000 nM). RIPK1-IN-34 offers substantial neuroprotection by inhibiting the phosphorylation of RIPK1, RIPK3, and mixed lineage kinase domain-like pseudokinase (MLKL) within the necroptosis pathway. RIPK1-IN-34 shows the neuroprotective effect in a rat middle cerebral artery occlusion (MCAO) model. RIPK1-IN-34 can be used for the study of anti-acute ischemic stroke (AIS).
    RIPK1-IN-34
  • HY-178465
    EP4 receptor antagonist 8 3068255-86-4
    EP4 receptor antagonist 8 is an orally active EP4 antagonist (human EP4 IC50 = 6.40 nM). EP4 receptor antagonist 8 significantly reduced paw and joint swelling, inflammatory cell infiltration, cartilage damage, pannus formation, and joint bone erosion in arthritis (AIA) mice in a dose-dependent manner. EP4 receptor antagonist 8 can be used for the study of inflammatory pain.
    EP4 receptor antagonist 8
  • HY-178470
    IDO1/TDO-IN-10
    IDO1/TDO-IN-10 (Compound G-14) is a dual IDO1 (EC50=3.07 μM) and TDO (EC50=9.7 μM) inhibitor. IDO1/TDO-IN-10 inhibits the conversion of tryptophan to kynurenine and modulates immune responses while reducing inflammatory reactions. IDO1/TDO-IN-10 is promising for research of cancers and inflammatory diseases.
    IDO1/TDO-IN-10
Cat. No. Product Name / Synonyms Application Reactivity